- Home
- TD vs GILD Comparison
TD vs GILD Comparison
Compare TD & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TD | GILD |
|---|---|---|
| Founded | 1855 | 1987 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 195.5B | 211.7B |
| IPO Year | 2025 | 2003 |
Fundamental Metrics
Financial Performance| Metric | TD | GILD |
|---|---|---|
| Price | $128.14 | $174.63 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 28 |
| Target Price | $119.65 | ★ $172.50 |
| AVG Volume (30 Days) | 1.4M | ★ 6.0M |
| Earning Date | 12-03-2026 | 10-29-2026 |
| Dividend Yield | ★ 2.51% | 1.96% |
| EPS Growth | N/A | ★ 1684.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $24,689,000,000.00 |
| Revenue This Year | $8.49 | $6.27 |
| Revenue Next Year | $5.67 | $7.22 |
| P/E Ratio | $11.65 | ★ N/A |
| Revenue Growth | N/A | ★ 9.98 |
| 52 Week Low | $79.52 | $116.88 |
| 52 Week High | $127.96 | $175.65 |
Technical Indicators
Market Signals| Indicator | TD | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 58.91 | 67.32 |
| Support Level | $116.42 | $142.91 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 1.84 | 4.07 |
| MACD | 0.34 | 1.35 |
| Stochastic Oscillator | 70.72 | 65.83 |
Price Performance
Historical ComparisonAbout TD Toronto Dominion Bank (The)
Toronto-Dominion is one of Canada's two largest banks with over CAD 2 trillion in assets by the end of April 2026. TD Bank operates four business segments: Canadian personal and commercial banking, US retail banking, wealth management and insurance, and wholesale banking. The bank derives more than 50% of its revenue from Canada and has dominant market shares in nearly all banking products and services. TD has around 44% of its revenue from its US operations. Its US footprint spans from Maine to Florida, with a strong presence in the Northeast.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).